Correlation of BRAF Mutation Status in Circulating-Free DNA and Tumor and Association with Clinical Outcome across Four BRAFi and MEKi Clinical Trials

Clinical Cancer Research

Volumn 22, Issue 3, 2016, Pages 567-574

  Santiago Walker, Ademi ^a,h   Gagnon, Robert ^a,i   Mazumdar, Jolly ^a   Casey, Michelle ^a,h   Long, Georgina V ^b   Schadendorf, Dirk ^c   Flaherty, Keith ^d   Kefford, Richard ^b,e   Hauschild, Axel ^f   Hwu, Patrick ^g   Haney, Patricia ^a,h   O'Hagan, Anne ^a,h   Carver, Jennifer ^a,i   Goodman, Vicki ^a,j   Legos, Jeffrey ^a,i   Martin, Anne Marie ^a,k  

^a GLAXOSMITHKLINE   (United States)

^b UNIVERSITY OF SYDNEY   (Australia)

^c UNIVERSITY HOSPITAL ESSEN   (Germany)

^d MASSACHUSETTS GENERAL HOSPITAL CANCER CENTER   (United States)

^e WESTMEAD HOSPITAL   (Australia)

^f UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

^g UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^h One Health Plaza ^*  (United States)

ⁱ NOVARTIS PHARMA AG   (Switzerland)

^j BRISTOL MYERS SQUIBB   (United States)

^k The Science Center Philadelphia   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

B RAF KINASE; CELL FREE DNA; DABRAFENIB; DACARBAZINE; DNA; PACLITAXEL; TRAMETINIB; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; CODON; MITOGEN ACTIVATED PROTEIN KINASE; PROTEIN KINASE INHIBITOR;

ARTICLE; BRAF GENE; CANCER PROGNOSIS; COHORT ANALYSIS; GENE MUTATION; GENETIC ASSOCIATION; HUMAN; MAJOR CLINICAL STUDY; MELANOMA; MONOTHERAPY; ONCOGENE; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; TREATMENT RESPONSE; AMINO ACID SUBSTITUTION; ANTAGONISTS AND INHIBITORS; BLOOD; CLINICAL TRIAL (TOPIC); CODON; FEMALE; GENETICS; KAPLAN MEIER METHOD; MALE; MOLECULARLY TARGETED THERAPY; MORTALITY; MUTATION; NEOPLASMS; PROGNOSIS; TREATMENT OUTCOME;

AMINO ACID SUBSTITUTION; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CLINICAL TRIALS AS TOPIC; CODON; DNA, NEOPLASM; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MITOGEN-ACTIVATED PROTEIN KINASES; MOLECULAR TARGETED THERAPY; MUTATION; NEOPLASMS; PROGNOSIS; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS B-RAF; TREATMENT OUTCOME;

EID: 84958978046     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-15-0321     Document Type: Article

References (30)

1. Crowley E, Di Nicolantonio F, Loupakis F, Bardelli A. Liquid biopsy: Monitoring cancer-genetics in the blood. Nat Rev Clin Oncol 2013; 10:472-84.
2. Diehl F, Schmidt K, Choti MA, Romans K, Goodman S, Li M, et al. Circulating mutant DNA to assess tumor dynamics. Nat Med 2008;14: 985-90.
3. Fleischhacker M, Schmidt B. Circulating nucleic acids (CNAs) and cancer-A survey. Biochimica et Biophysica Acta (BBA)-Reviews on Cancer 2007;1775:181-232.
4. Goebel G, Zitt M, Zitt M,Müller HM. Circulating nucleic acids in plasma or serum (CNAPS) as prognostic and predictive markers in patients with solid neoplasias. Dis Markers 2005;21:105-20.
5. Sidransky D. Emerging molecular markers of cancer. Nat Rev Cancer 2002;2:210-9.
6. Diaz LA Jr., Bardelli A. Liquid biopsies: Genotyping circulating tumor DNA. J Clin Oncol 2014;32:579-86.
7. Benesova L, Belsanova B, Suchanek S, Kopeckova M, Minarikova P, Lipska L, et al. Mutation-based detection and monitoring of cell-free tumor DNA in peripheral blood of cancer patients. Anal Biochem 2013;433:227-34.
8. SEER cancer statistics review, 1975-2012. based on November 2014 SEER data submission.[homepage on the Internet]. Bethesda, MD: National Cancer Institute. 2015 23 April [cited May 2015]. Available from: http://seer.cancer.gov/csr/1975-2012/.
9. Cancer facts & figures 2015 [homepage on the Internet]. Atlanta, GA, USA: American Cancer Society. 2015 [cited May 2015]. Available from: http://www.cancer.org/acs/groups/content/@editorial/documents/document/acspc-044552.pdf.
10. Greaves WO, Verma S, Patel KP, DaviesMA, Barkoh BA, Galbincea JM, et al. Frequency and spectrum of BRAF mutations in a retrospective, singleinstitution study of 1112 cases of melanoma. J Mol Diagn 2013;15:220-6.
11. Menzies AM, Haydu LE, Visintin L, Carlino MS, Howle JR, Thompson JF, et al. Distinguishing clinicopathologic features of patients with V600E and V600K BRAF-mutant metastatic melanoma. Clin Cancer Res 2012;18: 3242-9.
12. My cancer genome. BRAF c.1798-1799delGTinsAA (V600K) mutation in melanoma [homepage on the Internet]. Nashville, TN: Vanderbilt-Ingram Cancer Center 2015 March 6 [cited May 2015]. Available from: http://www.mycancergenome.org/content/disease/melanoma/braf/116.
13. DaviesH, Bignell GR, Cox C, Stephens P, Edkins S, Clegg S, et al.Mutations of the BRAF gene in human cancer. Nature 2002;417:949-54.
14. Flaherty KT, Puzanov I, Kim KB, Ribas A, McArthur GA, Sosman JA, et al. Inhibition of mutated, activated BRAF in metastatic melanoma. N Engl J Med 2010;363:809-19.
15. Falchook GS, Lewis KD, Infante JR, Gordon MS, Vogelzang NJ, DeMarini DJ, et al. Activity of the oral MEK inhibitor trametinib in patients with advanced melanoma: a phase 1 dose-escalation trial. Lancet Oncol 2012;13:782-9.
16. Falchook GS, Long GV, Kurzrock R, Kim KB, Arkenau TH, BrownMP, et al. Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: A phase 1 dose-escalation trial. Lancet 2012;379: 1893-901.
17. DaniottiM, Vallacchi V, Rivoltini L, Patuzzo R, SantinamiM, Arienti F, et al. Detection of mutated BRAF V600E variant in circulating DNA of stage III-IV melanoma patients. Int J Cancer 2007;120:2439-44.
18. Yancovitz M, Yoon J, Mikhail M, Gai W, Shapiro RL, Berman RS, et al. Detection of mutant BRAF alleles in the plasma of patients with metastatic melanoma. J Mol Diagn 2007;9:178-83.
19. Shinozaki M, O'Day SJ, Kitago M, Amersi F, Kuo C, Kim J, et al. Utility of circulating B-RAF DNA mutation in serum for monitoring melanoma patients receiving biochemotherapy. Clin Cancer Res 2007;13:2068-74.
20. Board RE, Ellison G, Orr M, Kemsley K, McWalter G, Blockley L, et al. Detection of BRAF mutations in the tumour and serum of patients enrolled in the AZD6244 (ARRY-142886) advanced melanoma phase II study. Br J Cancer 2009;101:1724-30.
21. Bidard F, Madic J, Mariani P, Piperno-Neumann S, Rampanou A, Servois V, et al. Detection rate and prognostic value of circulating tumor cells and circulating tumor DNA in metastatic uveal melanoma. Int J Cancer 2014; 134:1207-13.
22. Ascierto PA, Minor D, Ribas A, Lebbe C, O'Hagan A, Arya N, et al. Phase II trial (BREAK-2) of the BRAF inhibitor dabrafenib (GSK2118436) in patients with metastatic melanoma. J Clin Oncol 2013;31:3205-11.
23. Hauschild A, Grob JJ, Demidov LV, Jouary T, Gutzmer R, Millward M, et al. Dabrafenib in BRAF-mutated metastatic melanoma: A multicentre, openlabel, phase 3 randomised controlled trial. Lancet 2012;380:358-65.
24. Long GV, Trefzer U, Davies MA, Kefford RF, Ascierto PA, Chapman PB, et al. Dabrafenib in patients with Val600Glu or Val600Lys BRAF-mutant melanoma metastatic to the brain (BREAK-MB): A multicentre, open-label, phase 2 trial. Lancet Oncol 2012;13:1087-95.
25. Flaherty KT, Robert C, Hersey P, Nathan P, Garbe C, Milhem M, et al. Improved survival with MEK inhibition in BRAF-mutated melanoma. N Engl J Med 2012;367:107-14.
26. Dressman D, Yan H, Traverso G, Kinzler KW, Vogelstein B. Transforming singleDNAmolecules into fluorescentmagnetic particles for detection and enumeration of genetic variations. Proc Natl Acad Sci U S A 2003;100: 8817-22.
27. Diehl F, Li M, Dressman D, He Y, Shen D, Szabo S, et al. Detection and quantification of mutations in the plasma of patients with colorectal tumors. Proc Natl Acad Sci U S A 2005;102:16368-73.
28. Bettegowda C, Sausen M, Leary RJ, Kinde I, Wang Y, Agrawal N, et al. Detection of circulating tumor DNA in early-And late-stage human malignancies. Sci Transl Med 2014;6:224ra24.
29. Lipson EJ, Velculescu VE, Pritchard TS, Sausen M, Pardoll DM, Topalian SL, et al. Circulating tumorDNAanalysis as a real-timemethod for monitoring tumor burden in melanoma patients undergoing treatment with immune checkpoint blockade. J Immunother Cancer 2014;2:1-7.
30. Dawson S, Tsui DW, Murtaza M, Biggs H, RuedaOM, Chin S, et al. Analysis of circulating tumorDNAto monitormetastatic breast cancer.NEngl JMed 2013;368:1199-209.